Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.


SecurityEYEG / Eyegate Pharmaceuticals Inc. (30233M107)
President and CEOFROM STEPHEN
IndustryPharmaceutical Preparations
Institutional Owners21
Institutional Shares17,292,859 - 39.81%
Common Shares Outstanding43,439,130 shares (as of 2018-06-30)
Institutional Value$ 9,178,000 USD
Related EYEGW / Eyegate Pharmaceuticals Inc. Warrants

Institutional Stock Ownership and Shareholders()

EYEG / Eyegate Pharmaceuticals Inc. Institutional Ownership

Eyegate Pharmaceuticals Inc. (NASDAQ:EYEG) has 21 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 17,292,859 shares. Largest shareholders include Armistice Capital, Llc, Vanguard Group Inc, Essex Investment Management Co Llc, Barclays Plc, Us Bancorp \de\, IFP Advisors, Inc, Citadel Advisors Llc, Credit Suisse Ag/, Wedbush Securities Inc, and Raymond James Financial Services Advisors, Inc..
Eyegate Pharmaceuticals Inc. (NASDAQ:EYEG) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-09 13F-HR BlackRock Inc. 635 635 0.00 0 0
2018-08-07 13F-HR IFP Advisors, Inc 26,800 26,800 0.00 10 14 40.00
2018-08-14 13F-HR/A CITADEL ADVISORS LLC 56,628 25,851 -54.35 22 14 -36.36
2018-07-17 13F-HR ESSEX INVESTMENT MANAGEMENT CO LLC 73,492 39
2018-08-14 13F-HR CREDIT SUISSE AG/ 26,500 22,000 -16.98 10 12 20.00
2018-08-14 13F-HR Holistic Financial Partners 1,900 0 -100.00 1 0 -100.00
2018-08-14 13F-HR ROYAL BANK OF CANADA 12,356 12,355 -0.01 5 7 40.00
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 100 100 0.00 0 0
2018-08-14 13F-HR VANGUARD GROUP INC 73,949 114,949 55.44 28 61 117.86
2018-08-14 13F-HR TWO SIGMA SECURITIES, LLC 12,603 0 -100.00 5 0 -100.00
2018-08-13 13F-HR Vantage Investment Advisors, LLC 6,500 6,500 0.00 2 3 50.00
2018-07-30 13F-HR Raymond James Financial Services Advisors, Inc. 15,000 8
2017-02-10 13F-HR BlackRock Fund Advisors 10,254 10,352 0.96 18 17 -5.56
2018-08-06 13F-HR Bank of New York Mellon Corp 28,835 0 -100.00 11 0 -100.00
2018-07-24 13F-HR ACADIAN ASSET MANAGEMENT LLC 16,671 0 -100.00 6 0 -100.00
2018-08-14 13F-HR BARCLAYS PLC 52,569 65,500 24.60 20 35 75.00
2017-02-10 13F-HR BlackRock Investment Management, LLC 728 728 0.00 1 1 0.00
2018-08-08 13F-HR US BANCORP \DE\ 40,650 40,650 0.00 15 22 46.67
2018-08-03 13F-HR WEDBUSH SECURITIES INC 20,000 20,000 0.00 8 11 37.50
2018-08-14 13F-HR NORTHERN TRUST CORP 14,553 14,553 0.00 6 8 33.33
2018-08-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 9,226 9,226 0.00 4 4 0.00
2018-08-14 13F-HR UBS Group AG 1,537 14,316 831.42 1 8 700.00
2018-08-14 13F-HR Invesco Ltd. 11,612 6
2018-08-14 13F-HR MORGAN STANLEY 7,721 5,740 -25.66 3 3 0.00
2018-08-14 13F-HR ARMISTICE CAPITAL, LLC 1,192,000 16,802,500 1,309.61 453 8,905 1,865.78

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

Related News Stories

Your Daily Pharma Scoop: Biohaven In Pivotal Stage, Merck Trial Positive, FDA Waives EyeGate

2018-07-27 seekingalpha
Discussion: Biohaven Pharmaceutical Holding Company (BHVN) commences Phase 2/3 trial of its candidate BHV-4157 (trigriluzole) in patients with mild-to-moderate Alzheimer's disease (‘AD). Patient enrollment is expected to begin shortly. Following details of the study plan have been shared by the company. During the 48-week trial period, the 292-subject study will be randomized between trigriluzole and placebo. (10-2)

Reader Inquiry: Time To Buy EyeGate Pharmaceuticals?

2018-05-18 seekingalpha
Shares of fallen nearly 70% year to date but appear to be ready to fill the gap back to the psychologically important $1 level. (22-3)

Your Daily Pharma Scoop: Intercept's OCA, MediciNova In NASH, Pulse Biosciences Data

2018-04-16 seekingalpha
Intercept Pharmaceuticals (ICPT) reported clinical data from a liver biopsy-based substudy from its phase 3 POISE study. The study indicated that long-term OCA treatment in patients with PBC led to reversal or stabilization of fibrosis and cirrhosis. (143-3)

Office Depot, Dominion Energy Fall into Friday’s 52-Week Low Club

2018-04-13 247wallst
April 13, 2018: Here are four stocks trading with heavy volume among 52 equities making new 52-week lows in Friday’s session. On the NYSE decliners led advancers by about 3 to 2 and on the Nasdaq, decliners led advancers by about 9 to 5. (19-0)

Your Daily Pharma Scoop: Acadia Sell-Off, Therapix Soars On Results, Menlo Setback

2018-04-10 seekingalpha
Today we will discuss Acadia Pharmaceuticals (NASDAQ:ACAD), which has fallen sharply on a CNN report that raised concerns about the Nuplazid’s safety. (210-4)

Silicon Investor Message Boards

This table lists all message boards related to EYEG / Eyegate Pharmaceuticals Inc. on message board site Silicon Investor.

EYES Second Sight-Eyeglasses for the Blind help them see EYES Second Sight-Eyeglasses for the Blind help them see EYES Second Sight-Eyeglasses for the Blind help them see
CUSIP: 30233M107